Skip to search formSkip to main contentSkip to account menu

phenoxodiol

Known as: 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl), Idronoxil, 7-hydroxy-3-hydroxyphenyl-1H-benzopyran 
A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Isoflavones
NCIt Antineoplastic Agent Terminology

Narrower (1)

NV-06

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
ADVANCES OF PLANT-DERIVED NATURAL PRODUCTS IN OVARIAN CANCER THERAPY
Ovarian cancer is the leading cause of death in the gynaecologic cancers within the UK and US. Presently the standard treatment… 
2014
2014
The Effects of Combination Treatment Using Phenoxodiol and Docetaxel, and Phenoxodiol and Secreted Frizzled-related Protein 4 on Prostate Cancer Cell Lines
Although much progress has been made for the treatment of prostate cancer, patients with advanced prostate cancer still have a… 
2014
2014
Phenoxodiol glucoside compounds, preparing method thereof and pharmaceutical compositions containing the same as active ingredients
The present invention relates to a compound represented by chemical formula 1, or pharmaceutically acceptable salt thereof. In… 
2012
2012
Investigating the cytotoxic effects of the isoflavone, phenoxodiol, on prostate cancer cells
2010
2010
A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes.
4661 Background: Phenoxodiol is a synthetic isoflavone compound with broad anti-tumor activity that inhibits in vitro prostate… 
Review
2010
Review
2010
FDA Pipeline Preview, August 2010 (Naproxcinod, Ticagrelor, Phenoxodiol, CBLB502, TOL101, Oral kinase inhibitor, GVAX CML vaccine, TXA127, Sapacitabine or CYC682, ICT-107, Perifosine or KRX-0401…
Recent FDA action (through, July 2010) related to Naproxcinod, Ticagrelor, Phenoxodiol, CBLB502, TOL101, Oral kinase inhibitor… 
2008
2008
Phenoxodiol—A Chemosensitizer in the Midst of Cancer Chemoresistance
Phenoxodiol ([2H-1-Benzopyran-7-ol, 3-(4-hydrophyphenyl] (PXD) is a synthetic derivative of genistein, a naturally occurring… 
2008
2008
tNOX (ENOX2) Target for Chemosensitization-Low-Dose Responses in the Hormetic Concentration Range
An emerging concept of cancer chemotherapy is that of chemosensitization. Most often applied to the treatment of drug-resistance… 
Review
2006
Review
2006
Spotlight on tNOX: a tumor-selective target for cancer therapies.
Tumor-associated NOX (tNOX) is a novel cell surface ECTO-NOX protein that represents a promising target for selective antitumor… 
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving…